Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study

NCT02700464 is registered in ClinicalTrials.gov with Nucleix Ltd. as lead sponsor.

NCT NCT02700464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02700464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study
Lead sponsor
Nucleix Ltd.
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2016
Completion date
July 31, 2020
Enrollment
680 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer